Active pharmaceutical ingredient (API) Global Market – Forecast To 2027
Publishing Date : | March, 2021 |
Report Code : | HCPH 0100 |
Price: |
Single license $4,950
Site license $6,750 Global license $9,000 |
Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having a direct effect on disease treatment. APIs are synthesized by chemical synthesis, fermentation, biotechnological methods or enhanced from the natural source. According to IQ4I analysis, the global Active Pharmaceutical Ingredient market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $364,169.4 million by 2027. Adoption of biologics in disease management and increasing regulatory approvals in the past year, increasing scope of HPAPI market, patent expiration of major drugs, increasing trend of outsourcing, and increase in geriatric population are some of the factors driving the market growth. The global API market is mainly segmented by synthesis, by business type, by application, and by geography.
The global API market based on synthesis is further divided into synthetic API, Biotech API, and HPAPI. By synthesis, the synthetic API held the major share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The major factors driving the synthetic chemical API market are patent expiration of synthetic (small molecule drugs), an increasing number of small molecules in clinical trials, increasing outsourcing by the pharmaceutical companies, CMOs investments to expand manufacturing facilities, rise in the incidence of chronic and age-related diseases, rapid growth in the oncology market, technological advancement like cryogenic and continuous flow manufacturing. Biotech API accounted for the share of xx% in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. Increased investment in R&D by pharmaceutical companies for developing biologic drugs, adoption of biological therapies in disease management, increasing outsourcing, increasing biologics approvals in the past year, increasing chronic and autoimmune illnesses, increasing number of branded drugs going off-patent creating a scope for biosimilars, requirement of novel biologics therapeutics for rare diseases, increasing demand for antibody conjugates, bi or multispecific monoclonal antibodies, and vaccines to contain novel coronavirus infections are few factors driving the biotech API market.
Biotech API is further segmented into monoclonal antibodies, recombinant proteins, vaccines, and others (stem cell therapy and gene therapy). Monoclonal antibodies accounted for the largest share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The development of next-generation antibodies such as antibody-drug conjugates and rising venture capital investments and applications of monoclonal antibodies are the factors booming monoclonal antibodies market growth. The vaccine segment is forecasted to grow at a low teen CAGR from 2020 to 2027 owing to the worldwide demand for novel vaccines to treat the coronavirus diseases which emerged as a global pandemic.
Based on the customer base, the global biotech API is further segmented into biologics and biosimilars. Biologics accounted for the largest share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The Biologics market is driven globally due to the adoption of biological therapies in disease management, increasing biologics approvals in the past year, increasing chronic and autoimmune illnesses, and increasing the elderly population. Biosimilars accounted for the share of xx% in 2020 and is expected to grow at an exponential CAGR from 2020 to 2027 owing to patent expiry of biological drugs, low cost compared to biologics, increase in chronic diseases, growing geriatric population, and demand for quality healthcare.
Based on the customer base, the global synthetic API is further divided into branded API and generic API. The Branded API accounted for the largest share in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027. The Generic API is expected to grow at a high single digit CAGR from 2020 to 2027, due to the patent expiry of blockbuster drugs, rising healthcare expenses, and shift towards generic medicines led by government initiatives.
By business type, the global API market is divided into captive API and merchant API. The Captive market held the major share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The captive API is further divided into branded captive API and generic captive API. The branded captive API accounted for the largest share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027 owing to patent protection of blockbuster drugs. The Merchant API market is further divided into branded merchant API and generic merchant API. The Generic merchant API accounted for the largest share in 2020 and is expected to grow at a low teen CAGR from 2020 to 2027. Increasing outsourcing, advanced manufacturing facilities, lack of in-house manufacturing capability, high capital investment, and cost of API manufacturing are some of the factors driving the Merchant API market.
By therapeutic applications, the global API market is segmented into infectious diseases, oncology, cardiovascular disorders, central nervous system, pulmonary disorder, gastrointestinal disorder, endocrine disorders, metabolic disorders, genito-urinary disorders, musculoskeletal disorders, and others such as others such as ophthalmology, autoimmune diseases, ENT, dental, dermatology, and pain management. In the application segment, infectious disease accounted for the largest share in 2020 because of the global-wide rapid spread of COVID-19 and increased incidence of other infectious diseases such as tuberculosis, HIV, pneumonia, influenza, hepatitis, and others. The oncology division is expected to grow at a double digit CAGR from 2020 to 2027 driven mainly by the rising incidence of cancer cases, lifestyle changes, increasing geriatric population, high demand for anti-cancer drugs. Currently, there is a trend towards precision medicine which further boosts the global oncology API market growth.
The global API market by therapeutic application is segmented into synthetic API application, biotech API application, and HPAPI application market. In synthetic API application, infectious disease accounted for the largest share in 2020 and oncology is expected to grow at a high single digit CAGR from 2020 to 2027. Under biotech API and HPAPI, the oncology segmented contributed for the largest share of xx% and xx% in 2020 respectively, and is forecasted to grow at a high single digit CAGR of xx% and xx% from 2020 to 2027.
The active pharmaceutical Ingredients market by region is segmented as North America, Europe, Asia-Pacific, and the Rest of the world (ROW). By geography, North America held the largest share in 2020 due to patent expiration of the major drugs, rising demand for biotech APIs, market entry of biosimilars, increasing scope of highly potent drugs, and increase in the prevalence of chronic diseases such as cancer, cardiac disease, diseases associated with central nervous system, and musculoskeletal disorder coupled with high healthcare expenditure. Asia-Pacific is the fastest-growing region with a high single digit CAGR from 2020 to 2027 owing to low labor cost, abundance availability of raw materials, infrastructure facility, rise in generic drug demand, increased production capabilities, the presence of a large number of domestic and international players, and concentration of CMO companies.
Some of the key players of Active pharmaceutical Ingredient (API) market are Lonza Group (Switzerland), Boehringer Ingelheim GmbH (Germany), Teva Pharmaceutical Industries Ltd (Israel), Sanofi S.A. (France), Thermo Fisher Sceintific Inc. (Patheon N.V, U.S), Divis Laboratories (India), Olon S.p.A (Italy), Pfizer Inc. (U.S.), Permira funds (Cambrex Corporation U.K.), Carlyle Group (AMRI, U.S.), and others.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
- North America
- U.S.
- Rest of North America
- Europe
- Italy
- Germany
- France
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Rest of APAC
- Rest of the World (RoW)
- Brazil
- Rest of Latin America
- Middle East and Others
- 1 EXECUTIVE SUMMARY
- 2 INTRODUCTION
- 2.1 KEY TAKEAWAYS
- 2.2 SCOPE OF THE REPORT
- 2.3 REPORT DESCRIPTION
- 2.4 MARKETS COVERED
- 2.5 STAKEHOLDERS
- 2.6 RESEARCH METHODOLOGY
- 2.6.1 MARKET SIZE ESTIMATION
- 2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.6.3 SECONDARY SOURCES
- 2.6.4 PRIMARY SOURCES
- 2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
- 2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
- 2.6.7 ASSUMPTIONS
- 3 MARKET ANALYSIS
- 3.1 INTRODUCTION
- 3.2 MARKET SEGMENTATION
- 3.3 FACTORS INFLUENCING MARKET
- 3.3.1 DRIVERS AND OPPORTUNITIES
- 3.3.1.1 INCREASING INCIDENCE AND PREVALENCE OF CHRONIC DISEASES
- 3.3.1.2 ADOPTION OF BIOLOGICS IN DISEASE MANAGEMENT AND INCREASING REGULATORY APPROVALS IN THE PAST YEAR
- 3.3.1.3 INCREASING SCOPE OF HPAPI MARKET
- 3.3.1.4 PATENT EXPIRATION OF MAJOR DRUGS
- 3.3.1.5 INCREASING TREND OF OUTSOURCING
- 3.3.1.6 INCREASE IN THE GERIATRIC POPULATION
- 3.3.2 RESTRAINTS AND THREATS
- 3.3.2.1 CONTAMINATION OF API
- 3.3.2.2 HIGH COST FOR MANUFACTURING APIS
- 3.3.2.3 A REQUIREMENT OF HIGHLY SKILLED TECHNICIANS
- 3.3.2.4 FIERCE COMPETITION BETWEEN API PLAYERS
- 3.3.2.5 STRINGENT REGULATORY POLICIES AND ENVIRONMENTAL CONCERNS
- 3.4 REGULATORY AFFAIRS
- 3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
- 3.4.1.1 ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM
- 3.4.1.2 ISO 13408 ASEPTIC PROCESSING
- 3.4.1.3 ISO 14644-1 CLEAN ROOM STANDARDS
- 3.4.2 U.S.
- 3.4.3 CANADA
- 3.4.4 MEXICO
- 3.4.5 EUROPE
- 3.4.6 CHINA
- 3.4.7 INDIA
- 3.4.8 JAPAN
- 3.4.9 AUSTRALIA
- 3.4.10 SOUTH KOREA
- 3.4.11 LATIN AMERICA
- 3.4.12 MIDDLE EAST
- 3.5 TECHNOLOGICAL ADVANCEMENTS
- 3.5.1 INTRODUCTION
- 3.5.2 AUTOMATION AND CONTROL
- 3.5.3 CONTINUOUS MANUFACTURING
- 3.5.4 CRYOGENIC TECHNOLOGY
- 3.5.5 SINGLE - USE SYSTEM (SUS)
- 3.5.6 MAMMALIAN CELL BASED PRODUCTION
- 3.5.7 CELL FREE BASED APPROACH FOR THE PRODUCTION OF PROTEINS
- 3.5.8 ADVANCEMENTS IN HPAPI MANUFACTURING
- 3.6 PORTER'S FIVE FORCE ANALYSIS
- 3.6.1 THREAT OF NEW ENTRANTS
- 3.6.2 THREAT OF SUBSTITUTES
- 3.6.3 BARGAINING POWER OF SUPPLIERS
- 3.6.4 BARGAINING POWER OF BUYERS
- 3.6.5 COMPETITIVE RIVALRY
- 3.7 SUPPLY CHAIN ANALYSIS
- 3.8 MARKET SHARE ANALYSIS
- 3.9 FDA APPROVED API MANUFACTURING UNITS
- 3.10 PHARMACEUTICAL API PRODUCTION VOLUME
- 3.11 PATENT EXPIRY AND ANDA APPROVALS
- 3.12 DRUG MASTER FILING (DMF)
- 3.13 NOTICE OF INSPECTIONAL OBSERVATIONS (FORM 483)
- 3.14 REPURPOSED DRUGS FOR COVID-19 TREATMENT
- 3.15 ACQUISITION, MERGER, AND EXPANSIONS
- 3.16 COLLABORATION AND AGREEMENT BETWEEN API MANUFACTURERS
- 3.17 SELECTED TOP SELLING API
- 3.18 API MANUFACTURERS REVENUE AND CAPABILITIES TABLE
- 4 API GLOBAL MARKET, BY SYNTHESIS
- 4.1 INTRODUCTION
- 4.2 SYNTHETIC API
- 4.2.1 SYNTHETIC API BY CUSTOMER BASE
- 4.2.1.1 BRANDED SYNTHETIC API
- 4.2.1.2 GENERIC SYNTHETIC API
- 4.3 BIOTECH API
- 4.3.1 INTRODUCTION
- 4.3.1.1 MONOCLONAL ANTIBODIES
- 4.3.1.2 RECOMBINANT PROTEINS
- 4.3.1.3 VACCINES
- 4.3.1.4 OTHER BIOTECH API (CELL AND GENE THERAPY)
- 4.3.2 BIOTECH API BY CUSTOMER BASE
- 4.3.2.1 BIOLOGIC API
- 4.3.2.2 BIOSIMILAR API
- 4.4 HPAPI
- 4.4.1 HPAPI BY CUSTOMER BASE
- 4.4.1.1 BRANDED HPAPI
- 4.4.1.2 GENERIC HPAPI
- 5 API GLOBAL MARKET, BY BUSINESS TYPE
- 5.1 INTRODUCTION
- 5.2 CAPTIVE API BY TYPE
- 5.2.1 BRANDED CAPTIVE API
- 5.2.2 GENERIC CAPTIVE API
- 5.3 MERCHANT API BY TYPE
- 5.3.1 BRANDED MERCHANT API
- 5.3.2 GENERIC MERCHANT API
- 6 API GLOBAL MARKET, BY APPLICATION
- 6.1 INTRODUCTION
- 6.2 INFECTIOUS DISEASES
- 6.3 ONCOLOGY
- 6.4 CARDIOVASCULAR DISEASES
- 6.5 CENTRAL NERVOUS SYSTEM
- 6.6 PULMONARY DISORDERS
- 6.7 GASTROINTESTINAL DISORDERS
- 6.8 ENDOCRINE DISORDERS
- 6.9 METABOLIC DISORDERS
- 6.10 GENITOURINARY DISORDERS
- 6.11 MUSCULOSKELETAL DISORDERS
- 6.12 OTHER APPLICATIONS (ANAESTHASIA, AUTOIMMUNE DISEASES, OPTHALMOLOGY, DENTAL, PAIN MANAGEMENT, GYNAECOLOGY, DERMATOLOGY AND ENT)
- 7 REGIONAL ANALYSIS
- 7.1 INTRODUCTION
- 7.2 NORTH AMERICA
- 7.2.1 U.S.
- 7.2.2 REST OF NORTH AMERICA
- 7.3 EUROPE
- 7.3.1 ITALY
- 7.3.2 GERMANY
- 7.3.3 FRANCE
- 7.3.4 REST OF EUROPE
- 7.4 APAC
- 7.4.1 CHINA
- 7.4.2 JAPAN
- 7.4.3 INDIA
- 7.4.4 REST OF APAC
- 7.5 ROW
- 7.5.1 BRAZIL
- 7.5.2 REST OF LATAM
- 7.5.3 MIDDLE EAST & OTHERS
- 8 COMPETITIVE LANDSCAPE
- 8.1 INTRODUCTION
- 8.2 PRODUCT APPROVALS
- 8.3 AGREEMENTS
- 8.4 EXPANSIONS
- 8.5 COLLABORATIONS
- 8.6 PRODUCT LAUNCH
- 8.7 PARTNERSHIP
- 8.8 ACQUISITIONS
- 8.9 OTHERS
- 9 MAJOR COMPANIES
- 9.1 CARLYLE GROUP (ALBANY MOLECULAR RESEARCH INC)
- 9.1.1 OVERVIEW
- 9.1.2 FINANCIALS
- 9.1.3 PRODUCT PORTFOLIO
- 9.1.4 KEY DEVELOPMENTS
- 9.1.5 BUSINESS STRATEGY
- 9.1.6 SWOT ANALYSIS
- 9.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- 9.2.1 OVERVIEW
- 9.2.2 FINANCIALS
- 9.2.3 PRODUCT PORTFOLIO
- 9.2.4 KEY DEVELOPMENTS
- 9.2.5 BUSINESS STRATEGY
- 9.2.6 SWOT ANALYSIS
- 9.3 DIVIS LABORATORIES
- 9.3.1 OVERVIEW
- 9.3.2 FINANCIALS
- 9.3.3 PRODUCT PORTFOLIO
- 9.3.4 KEY DEVELOPMENTS
- 9.3.5 BUSINESS STRATEGY
- 9.3.6 SWOT ANALYSIS
- 9.4 LONZA GROUP LTD.
- 9.4.1 OVERVIEW
- 9.4.2 FINANCIALS
- 9.4.3 PRODUCT PORTFOLIO
- 9.4.4 KEY DEVELOPMENTS
- 9.4.5 BUSINESS STRATEGY
- 9.4.6 SWOT ANALYSIS
- 9.5 OLON S.P.A.
- 9.5.1 OVERVIEW
- 9.5.2 FINANCIALS
- 9.5.3 PRODUCT PORTFOLIO
- 9.5.4 KEY DEVELOPMENTS
- 9.5.5 BUSINESS STRATEGY
- 9.5.6 SWOT ANALYSIS
- 9.6 PERMIRA FUNDS (CAMBREX CORPORATION U.K.)
- 9.6.1 OVERVIEW
- 9.6.2 FINANCIALS
- 9.6.3 PRODUCT PORTFOLIO
- 9.6.4 KEY DEVELOPMENTS
- 9.6.5 BUSINESS STRATEGY
- 9.6.6 SWOT ANALYSIS
- 9.7 PFIZER INC.
- 9.7.1 OVERVIEW
- 9.7.2 FINANCIALS
- 9.7.3 PRODUCT PORTFOLIO
- 9.7.4 KEY DEVELOPMENTS
- 9.7.5 BUSINESS STRATEGY
- 9.7.6 SWOT ANALYSIS
- 9.8 SANOFI
- 9.8.1 OVERVIEW
- 9.8.2 FINANCIALS
- 9.8.3 PRODUCT PORTFOLIO
- 9.8.4 KEY DEVELOPMENTS
- 9.8.5 BUSINESS STRATEGY
- 9.8.6 SWOT ANALYSIS
- 9.9 TEVA PHARMACEUTICAL INDUSTRIES LIMITED.
- 9.9.1 OVERVIEW
- 9.9.2 FINANCIALS
- 9.9.3 PRODUCT PORTFOLIO
- 9.9.4 KEY DEVELOPMENTS
- 9.9.5 BUSINESS STRATEGY
- 9.9.6 SWOT ANALYSIS
- 9.10 THERMO FISHER SCIENTIFIC INC
- 9.10.1 OVERVIEW
- 9.10.2 FINANCIALS
- 9.10.3 PRODUCT PORTFOLIO
- 9.10.4 KEY DEVELOPMENTS
- 9.10.5 BUSINESS STRATEGY
- 9.10.6 SWOT ANALYSIS
- TABLE 1 API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 2 GLOBAL SMALL MOLECULE API REVENUE ($MN), AVERAGE SELLING PRICE ($/KG) AND PRODUCTION IN TONS, BY APPLICATION (2020)
- TABLE 3 GLOBAL SMALL MOLECULE VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2019-2027) (MILLION LITRES)
- TABLE 4 GLOBAL SMALL MOLECULE API PRODUCTION, BY APPLICATION, (2019-2027) (TONS)
- TABLE 5 GLOBAL BIOLOGICS VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2019-2027) (MILLION LITRES)
- TABLE 6 GLOBAL SMALL MOLECULE API PRODUCTION, (2019-2027) (METRIC TONS)
- TABLE 7 GLOBAL BIOLOGICS API PRODUCTION, (2019-2027) (METRIC TONS)
- TABLE 8 GLOBAL API PRODUCTION, (2019-2027) (METRIC TONS)
- TABLE 9 PATENT EXPIRY OF SYNTHETIC API DRUGS, (2017 - 2022)
- TABLE 10 PATENT EXPIRY OF BIOTECH API DRUGS, (2018 - 2028)
- TABLE 11 ANDA APPROVALS: SMALL MOLECULES - GENERICS, (2020 - 2021)
- TABLE 12 ANDA APPROVALS: BIOSIMILARS, (2020)
- TABLE 13 COMPANIES ACQUISITION AND MERGER, (2018 - 2020)
- TABLE 14 EXPANSIONS, (2019 - 2021)
- TABLE 15 COLLABORATIONS AND AGREEMENTS, (2019 - 2021)
- TABLE 16 API GLOBAL MARKET REVENUE, BY SYNTHESIS, (2019-2027) ($MN)
- TABLE 17 SYNTHETIC API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 18 SYNTHETIC API GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
- TABLE 19 BRANDED SYNTHETIC API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 20 GENERIC SYNTHETIC API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 21 BIOTECH API GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
- TABLE 22 BIOTECH API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 23 MONOCLONAL ANTIBODIES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 24 RECOMBINANT PROTEINS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 25 VACCINES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 26 OTHER BIOTECH API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 27 BIOTECH API GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
- TABLE 28 BIOLOGIC API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 29 BIOSIMILAR API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 30 HPAPI GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 31 HPAPI GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
- TABLE 32 BRANDED HPAPI GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 33 GENERIC HPAPI GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 34 API GLOBAL MARKET REVENUE, BY BUSINESS TYPE, (2019-2027) ($MN)
- TABLE 35 CAPTIVE API GLOBAL MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
- TABLE 36 CAPTIVE API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 37 BRANDED CAPTIVE API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 38 GENERIC CAPTIVE API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 39 MERCHANT API GLOBAL MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
- TABLE 40 MERCHANT API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 41 BRANDED MERCHANT API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 42 GENERIC MERCHANT API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 43 API GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 44 SYNTHETIC API GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 45 BIOTECH API GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 46 HPAPI GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 47 INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 48 SYNTHETIC INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 49 BIOTECH INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 50 HPAPI INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 51 ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 52 SYNTHETIC ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 53 BIOTECH ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 54 HPAPI ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 55 CARDIOVASCULAR DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 56 SYNTHETIC CARDIOVASCULAR DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 57 BIOTECH CARDIOVASCULAR DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 58 HPAPI CARDIOVASCULAR DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 59 CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 60 SYNTHETIC CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 61 BIOTECH CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 62 HPAPI CENTRAL NERVOUS SYSTEM GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 63 PULMONARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 64 SYNTHETIC PULMONARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 65 BIOTECH PULMONARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 66 HPAPI PULMONARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 67 GASTROINTESTINAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 68 SYNTHETIC GASTROINTESTINAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 69 BIOTECH GASTROINTESTINAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 70 GASTROINTESTINAL DISORDERS HPAPI GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 71 ENDOCRINE DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 72 SYNTHETIC ENDOCRINE DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 73 BIOTECH ENDOCRINE DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 74 HPAPI ENDOCRINE DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 75 METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 76 SYNTHETIC METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 77 BIOTECH METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 78 HPAPI METABOLIC DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 79 GENITOURINARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 80 SYNTHETIC GENITOURINARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 81 BIOTECH GENITOURINARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 82 HPAPI GENITOURINARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 83 MUSCULOSKELETAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 84 SYNTHETIC MUSCULOSKELETAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 85 BIOTECH MUSCULOSKELETAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 86 HPAPI MUSCULOSKELETAL DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 87 OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 88 SYNTHETIC OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 89 BIOTECH OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 90 HPAPI OTHER APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 91 API GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
- TABLE 92 NORTH AMERICA API MARKET REVENUE, BY SYNTHESIS, (2019-2027) ($MN)
- TABLE 93 NORTH AMERICA BIOTECH API MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
- TABLE 94 NORTH AMERICA SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
- TABLE 95 NORTH AMERICA BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
- TABLE 96 NORTH AMERICA HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
- TABLE 97 NORTH AMERICA API MARKET REVENUE, BY BUSINESS TYPE, (2019-2027) ($MN)
- TABLE 98 NORTH AMERICA CAPTIVE API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
- TABLE 99 NORTH AMERICA MERCHANT API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
- TABLE 100 NORTH AMERICA API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 101 NORTH AMERICA SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 102 NORTH AMERICA BIOTECH API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 103 NORTH AMERICA HPAPI MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 104 NORTH AMERICA API MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
- TABLE 105 EUROPE API MARKET REVENUE, BY SYNTHESIS, (2019-2027) ($MN)
- TABLE 106 EUROPE BIOTECH API MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
- TABLE 107 EUROPE SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
- TABLE 108 EUROPE BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
- TABLE 109 EUROPE HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
- TABLE 110 EUROPE API MARKET REVENUE, BY BUSINESS TYPE, (2019-2027) ($MN)
- TABLE 111 EUROPE CAPTIVE API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
- TABLE 112 EUROPE MERCHANT API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
- TABLE 113 EUROPE API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 114 EUROPE SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 115 EUROPE BIOTECH API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 116 EUROPE HPAPI MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 117 EUROPE API MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
- TABLE 118 APAC API MARKET REVENUE, BY SYNTHESIS, (2019-2027) ($MN)
- TABLE 119 APAC BIOTECH API MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
- TABLE 120 APAC SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
- TABLE 121 APAC BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
- TABLE 122 APAC HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
- TABLE 123 APAC API MARKET REVENUE, BY BUSINESS TYPE, (2019-2027) ($MN)
- TABLE 124 APAC CAPTIVE API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
- TABLE 125 APAC MERCHANT API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
- TABLE 126 APAC API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 127 APAC SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 128 APAC BIOTECH API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 129 APAC HPAPI MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 130 APAC API MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
- TABLE 131 ROW API MARKET REVENUE, BY SYNTHESIS, (2019-2027) ($MN)
- TABLE 132 ROW BIOTECH API MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
- TABLE 133 ROW SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
- TABLE 134 ROW BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
- TABLE 135 ROW HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
- TABLE 136 ROW API MARKET REVENUE, BY BUSINESS TYPE, (2019-2027) ($MN)
- TABLE 137 ROW CAPTIVE API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
- TABLE 138 ROW MERCHANT API MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
- TABLE 139 ROW API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 140 ROW SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 141 ROW BIOTECH API MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 142 ROW HPAPI MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
- TABLE 143 ROW API MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
- TABLE 144 PRODUCT APPROVALS
- TABLE 145 AGREEMENTS
- TABLE 146 EXPANSIONS
- TABLE 147 COLLABORATIONS
- TABLE 148 PRODUCT LAUNCH
- TABLE 149 PARTNERSHIP
- TABLE 150 ACQUISITIONS
- TABLE 151 OTHERS
- TABLE 152 BOEHRINGER INGELHEIM: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
- TABLE 153 BOEHRINGER INGELHEIM: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
- TABLE 154 BOEHRINGER INGELHEIM: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
- TABLE 155 DIVIS LABORATORIES LTD: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
- TABLE 156 DIVIS LABORATORIES LTD: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) ($MN)
- TABLE 157 LONZA GROUP: TOTAL REVENUE & R&D EXPENSES (2018 -2020) ($MN)
- TABLE 158 LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
- TABLE 159 LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
- TABLE 160 PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2019) ($MN)
- TABLE 161 PFIZER INC: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
- TABLE 162 PFIZER INC: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
- TABLE 163 SANOFI: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
- TABLE 164 SANOFI: TOTAL REVENUE BY SEGMENT (2018-2020) ($MN)
- TABLE 165 SANOFI: TOTAL REVENUE BY REGION (2018-2020) ($MN)
- TABLE 166 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
- TABLE 167 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE BY SEGMENT (2018-2020) ($MN)
- TABLE 168 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE BY GEOGRAPHY (2018-2020) ($MN)
- TABLE 169 THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
- TABLE 170 THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
- TABLE 171 THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
- FIGURE 1 API GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
- FIGURE 2 RESEARCH METHODOLOGY: API GLOBAL MARKET
- FIGURE 3 API GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
- FIGURE 4 API GLOBAL MARKET: FORECASTING MODEL
- FIGURE 5 API GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
- FIGURE 6 API GLOBAL MARKET SEGMENTATION
- FIGURE 7 MARKET DYNAMICS
- FIGURE 8 API GLOBAL MARKET: PORTER'S ANALYSIS
- FIGURE 9 API GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
- FIGURE 10 GLOBAL API MARKET SHARE ANALYSIS, 2020 (%)
- FIGURE 11 FDA APPROVED GLOBAL API MANUFACTURING LANDSCAPE
- FIGURE 12 SMALL MOLECULE API PRODUCTION BY APPLICATION (2020), IN-HOUSE V/S CMO (2019 - 2027) (TONS) AND GLOBAL MANUFACTURING CAPACITIES (2020) (LITRES)
- FIGURE 13 GLOBAL TOTAL API AND CMO PRODUCTION (2019 - 2027) (METRIC TONS)
- FIGURE 14 PATENT EXPIRY OF SMALL MOLECULES (2017-2022)
- FIGURE 15 PATENT EXPIRY (2017-2022) AND ANDA APPROVALS (2020 -2021), BY APPLICATION SHARE (%)
- FIGURE 16 API DMF FILED BY COUNTRIES (2020) (NO'S)
- FIGURE 17 API DMF FILED, BY COMPANY (2020) (NO'S)
- FIGURE 18 FORM 483 NON-COMPLIANCE, BY COUNTRY (2020) (NO'S)
- FIGURE 19 API GLOBAL MARKET SHARE, BY SYNTHESIS, BY CUSTOMER BASE AND BIOTECH API BY PRODUCT TYPE (2020) (%)
- FIGURE 20 BIOTECH API GLOBAL MARKET SHARE, BY PRODUCT TYPE (2020) (%)
- FIGURE 21 VACCINES GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
- FIGURE 22 GENERIC HPAPI GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
- FIGURE 23 API GLOBAL MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API BY TYPE (2020) (%)
- FIGURE 24 CAPTIVE API GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
- FIGURE 25 API GLOBAL MARKET SHARE, BY APPLICATION (2020) (%), CAGR (%)
- FIGURE 26 SYNTHETIC API GLOBAL MARKET SHARE, BY APPLICATION (2020) (%), CAGR (%)
- FIGURE 27 BIOTECH API GLOBAL MARKET SHARE, BY APPLICATION, (2020) (%), CAGR (%)
- FIGURE 28 HPAPI GLOBAL MARKET SHARE, BY APPLICATION, (2020) %, CAGR (%)
- FIGURE 29 BIOTECH INFECTIOUS DISEASE API GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
- FIGURE 30 METABOLIC DISORDER API GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
- FIGURE 31 API GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%)
- FIGURE 32 API GLOBAL MARKET SHARE, BY REGION AND BY COUNTRY (2020) (%)
- FIGURE 33 NORTH AMERICA API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY PRODUCT TYPE (2020) (%)
- FIGURE 34 NORTH AMERICA SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%)
- FIGURE 35 NORTH AMERICA API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2020 V/S 2027) (%)
- FIGURE 36 NORTH AMERICA API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 37 NORTH AMERICA SYNTHETIC API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 38 NORTH AMERICA BIOTECH API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 39 NORTH AMERICA HPAPI MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 40 NORTH AMERICA API MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
- FIGURE 41 U.S. API MARKET REVENUE, BY SYNTHESIS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
- FIGURE 42 U.S. API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 43 U.S. SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 44 U.S. BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 45 U.S. HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 46 REST OF N.A. API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
- FIGURE 47 REST OF N.A. API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 48 REST OF N.A. SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 49 REST OF N.A. BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 50 REST OF N.A. HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 51 EUROPE API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY PRODUCT TYPE (2020) (%)
- FIGURE 52 EUROPE SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%)
- FIGURE 53 EUROPE API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2020 V/S 2027) (%)
- FIGURE 54 EUROPE API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 55 EUROPE SYNTHETIC API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 56 EUROPE BIOTECH API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 57 EUROPE HPAPI MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 58 EUROPE API MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
- FIGURE 59 ITALY API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
- FIGURE 60 ITALY API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 61 ITALY SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 62 ITALY BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 63 ITALY HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 64 GERMANY API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
- FIGURE 65 GERMANY API MARKET REVENUE, BY APPLICATION (2020V/S 2027) ($MN)
- FIGURE 66 GERMANY SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 67 GERMANY BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 68 GERMANY HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 69 FRANCE API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
- FIGURE 70 FRANCE API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 71 FRANCE SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 72 FRANCE BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 73 FRANCE HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 74 REST OF EUROPE API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
- FIGURE 75 REST OF EUROPE API MARKET REVENUE, BY APPLICATION (2020 V/S 202) ($MN)
- FIGURE 76 REST OF EUROPE SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 77 REST OF EUROPE BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 78 REST OF EUROPE HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 79 APAC API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY PRODUCT TYPE (2020 V/S 2027) (%)
- FIGURE 80 APAC SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%)
- FIGURE 81 APAC API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2020 V/S 2027) (%)
- FIGURE 82 APAC API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 83 APAC SYNTHETIC API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 84 APAC BIOTECH API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 85 APAC HPAPI MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 86 REST OF APAC API MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
- FIGURE 87 CHINA API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
- FIGURE 88 CHINA API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 89 CHINA SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
- FIGURE 90 CHINA BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 91 CHINA HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 92 JAPAN API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
- FIGURE 93 JAPAN API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 94 JAPAN SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 95 JAPAN BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 96 JAPAN HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 97 INDIA API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
- FIGURE 98 INDIA API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 99 INDIA SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 100 INDIA BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 101 INDIA HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 102 REST OF APAC API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
- FIGURE 103 REST OF APAC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 104 REST OF APAC SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 105 REST OF APAC BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 106 REST OF APAC HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 107 ROW API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY TYPE (2020 V/S 2027) (%)
- FIGURE 108 ROW SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%)
- FIGURE 109 ROW API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2020 V/S 2027) (%)
- FIGURE 110 ROW API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 111 ROW SYNTHETIC API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 112 ROW BIOTECH API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 113 ROW HPAPI MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
- FIGURE 114 ROW API SHARE, BY COUNTRY (2020 V/S 2027) (%)
- FIGURE 115 BRAZIL API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
- FIGURE 116 BRAZIL API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 117 BRAZIL SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 118 BRAZIL BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 119 BRAZIL HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 120 REST OF LATAM API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
- FIGURE 121 REST OF LATAM API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 122 REST OF LATAM SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 123 REST OF LATAM BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 124 REST OF LATAM HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 125 MIDDLE EAST & OTHERS API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN)
- FIGURE 126 MIDDLE EAST & OTHERS API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 127 MIDDLE EAST & OTHERS SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 128 MIDDLE EAST & OTHERS BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 129 MIDDLE EAST & OTHERS HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
- FIGURE 130 KEY GROWTH STRATEGIES, (2019-2021)
- FIGURE 131 SWOT: ALBANY MOLECULAR RESEARCH INC
- FIGURE 132 SWOT: BOEHRINGER INGELHEIM GMBH
- FIGURE 133 SWOT: DIVIS LABORATORIES
- FIGURE 134 SWOT: LONZA GROUP
- FIGURE 135 SWOT: OLON S.P.A
- FIGURE 136 SWOT: CAMBREX CORPORATION
- FIGURE 137 SWOT: PFIZER INC.
- FIGURE 138 SWOT: SANOFI
- FIGURE 139 SWOT: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- FIGURE 140 SWOT: THERMO FISHER SCIENTIFIC
- 1 Aarti Drugs Ltd.
- 2 AbbVie Inc.
- 3 AbCellera Biologics Inc.
- 4 Abclonal Inc.
- 5 Acadia Pharmaceuticals Inc.
- 6 Aceto
- 7 ACIC Pharmaceuticals Inc.
- 8 Adimmune corporation
- 9 Advance Pharmaceuticals, LLC
- 10 Aileron Therapeutics Inc.
- 11 Ajanta Pharma Limited
- 12 Ajinomoto Bio-Pharma
- 13 Albemarle Corporation
- 14 Alcami Corporation, Inc.
- 15 Alembic Pharmaceuticals Ltd.
- 16 Alkem Laboratories Ltd.
- 17 Alkermes Plc
- 18 Almac group
- 19 Almelo Private Limited
- 20 Alpic Remedies Ltd.
- 21 Alven Laboratories
- 22 Ambio Pharma Inc.
- 23 Amega Biotech S.A.
- 24 Amgen Inc.
- 25 Amneal Pharmaceuticals LLC
- 26 Amoytop Biotech
- 27 Angelini Holding S.p.A.
- 28 Aprogen
- 29 Aputit LLC
- 30 Aravive Inc.
- 31 Arena Pharmaceuticals, Inc.
- 32 Arevipharma GmbH
- 33 Artesan Pharma GmbH & Co. KG
- 34 Aspire Lifesciences Pvt., Ltd.
- 35 Astellas Pharma Inc.
- 36 AstraZeneca plc
- 37 Aurinia Pharmaceuticals Inc.
- 38 Aurobindo Pharma Ltd.
- 39 Avrobio Inc.
- 40 AZAD Pharmaceutical Ingredients AG
- 41 Bachem holding AG
- 42 Bal Pharma Ltd.
- 43 BASF SE
- 44 Baxter International Inc.
- 45 Bayer AG
- 46 Bio Elpida
- 47 Bio Genomics Ltd.
- 48 Bio Marin Pharmaceuticals Inc.
- 49 Biocin Healthcare
- 50 Biocon Ltd.
- 51 Biogen Inc.
- 52 BioNTech SE
- 53 Biophore India pharmaceuticals Pvt Ltd
- 54 Biosint S.p.A.
- 55 Biotechnica Pharma Global
- 56 Biovian
- 57 Blanver Farmoquimica
- 58 Boehringer Ingelheim GmbH
- 59 Brammer bio
- 60 Brawn Biotech Ltd.
- 61 Bright Path laboratories
- 62 Bristol-Meyers Squibb
- 63 Cadila Pharmaceuticals Ltd.
- 64 Carlyle Group (AMRI)
- 65 Catalent Inc.
- 66 Cayman chemical
- 67 Celltrion Healthcare
- 68 Century Pharmaceuticals Ltd.
- 69 Cerbios - pharma S.A.
- 70 CFM Group (AMSA S.P.A)
- 71 Changzhou Pharmaceutical Factory
- 72 ChemCon GmbH
- 73 China Chemical & Pharmaceutical Co., Ltd.
- 74 Chongqing Huapont Pharmaceutical Co., Ltd.
- 75 Cipla Limited
- 76 CKD Bio
- 77 Coba pharma S.L.U
- 78 Corden Pharma International GmbH
- 79 Cosmo Pharmaceuticals
- 80 CTX Life Sciences Pvt. Ltd.
- 81 Daiichi Sankyo Company, Limited
- 82 Daito Pharmaceutical Co., Ltd.
- 83 Dalton Pharma Services
- 84 DCS Pharma AG
- 85 Delpharm SAS
- 86 Dishman Carbogen Amcis Limited
- 87 Divis laboratories Ltd.
- 88 Dr. Reddy's Laboratories Ltd.
- 89 Eisai Co., Ltd.
- 90 Eli Lilly and Company
- 91 Elusys Therapeutic, Inc.
- 92 Emcure Pharmaceuticals Ltd.
- 93 Enaltec Labs Private Limited.
- 94 Eprius Biopharmaceuticals Inc.
- 95 Ercros S.A
- 96 Estechpharma Co., Ltd.
- 97 Esteve Química
- 98 Everest Organics Limited
- 99 Evonik Industries AG (Evonic healthcare)
- 100 F. Hoffmann-La Roche Ltd
- 101 Fabbrica Italiana Sintetici S.p.A.
- 102 Fareva S.A
- 103 Farmabios SpA
- 104 Farmhispania Group
- 105 Ferrer group (Interquim, S.A.)
- 106 Ferring Pharmaceuticals
- 107 Flamma S.p.A.
- 108 Florentis Pharmaceuticals Pvt., Ltd.
- 109 Formosa Laboratories Inc.
- 110 Fresenius SE & co. Kgaa
- 111 Fujifilm Corporation
- 112 Generex Biotechnology Corperation
- 113 Gentec Pharmaceutical Group S.A
- 114 Gilead Sciences, Inc.
- 115 GlaxoSmithKline plc
- 116 Glenmark Generics Ltd.
- 117 Gnosis S.p.A.
- 118 Granules India Ltd.
- 119 GVK Industries Limited (GVK Bioscience)
- 120 Haoyuan Chemexpress Co.Ltd.
- 121 Harbour BioMed
- 122 Harman Finochem Limited
- 123 Heni Chemical Industries
- 124 Heraues Holding GmbH
- 125 Hetero Labs Ltd.
- 126 Honour Lab Ltd.
- 127 Hovione
- 128 Huvapharma
- 129 Hybio Pharmaceutical Co., Ltd.
- 130 iBio Inc
- 131 Icrom SpA
- 132 Inabata France S.A.S.
- 133 Inalco S.p.A.
- 134 Indena S.p.A
- 135 Inpellis Inc.
- 136 Intas Pharmaceuticals Ltd.
- 137 Jeil Pharmaceutical Co. Ltd.
- 138 Johnson & Johnson
- 139 Jubilant Life Sciences
- 140 Katsura Chemical Co.,Ltd.
- 141 KBI Biopharma, Inc.
- 142 Kern Pharma, S.L.
- 143 Kleos pharma
- 144 Kongo Yakuhin Co., Ltd.
- 145 Kosher Pharmaceuticals
- 146 KYORIN Holdings, Inc. (KYORIN Pharmaceutical Co., Ltd.)
- 147 Lannett Co. Inc.
- 148 Laurus Labs.
- 149 Lebsa
- 150 LGM Pharma
- 151 Libbs Farmacêutica
- 152 Liptis Pharmaceuticals USA Inc.
- 153 Lonza Group
- 154 Lotus Pharmaceutical Co., Ltd.
- 155 Lupin Limited
- 156 Lusochimica S.p.A
- 157 Macleods pharmaceutical Ltd.
- 158 Magle Chemoswed AB
- 159 Mallinckrodt Pharmaceuticals
- 160 Medichem S.A
- 161 Megafine Pharma Ltd
- 162 Mehta API
- 163 Merck KGaA
- 164 Metrochem API
- 165 Micro Labs Ltd.
- 166 Minakem S.A
- 167 Moehs Iberica S.L.
- 168 Molcan Corporation
- 169 Morepen Laboratories Ltd.
- 170 MSN Laboratories Pvt.Ltd.
- 171 MViyeS Pharma Ventures Private Limited
- 172 Natco Pharma Ltd.
- 173 Neovacs
- 174 Neuland Laboratories Ltd
- 175 Neuraxpharm Arzneimittel GmbH
- 176 Nifty Labs Pvt Ltd.
- 177 Norchim SAS
- 178 Novartis International AG
- 179 Novasep Hodlings SAS
- 180 Novo Nordisk A/S
- 181 Novocap S.A.
- 182 Nuclius Lifesciences
- 183 Ofichem B.V.
- 184 Olainfarm AS
- 185 Olon S.p.A
- 186 Optimus Pharma Private Ltd.
- 187 Optum, Inc.
- 188 Orgenesis Inc.
- 189 Orion Oy (Fermion Oy)
- 190 Outlook Therapeutics, Inc.
- 191 Paratek pharmaceuticals Inc.
- 192 Permira funds (Cambrex Corporation)
- 193 Perrigo Company plc
- 194 Personalized Stem Cells, Inc.
- 195 Pfanstiehl Inc.
- 196 Pfizer Inc.
- 197 Pharmaceutical International Inc.
- 198 PharmaZell Group
- 199 Phyton Biotech LLC
- 200 Pierre Fabre Group
- 201 Piramal Pharma Solutions
- 202 Polpharma B2B
- 203 Prajna Generics Pvt. Ltd.
- 204 Precise Group
- 205 Precision BioSciences, Inc.
- 206 Princeton Biomolecular Research Inc
- 207 ProBiogen AG
- 208 Prozomix Limited
- 209 Raks Pharma Pvt Ltd.
- 210 Recipharm AB
- 211 Regeneron Pharmaceuticals, Inc.
- 212 Reine Lifescience
- 213 Reva Pharma Pvt., Ltd.
- 214 Rinque pharma S.A
- 215 Rochem International Inc.
- 216 RPG Life Sciences Ltd.
- 217 Rxn Chemicals Pvt. Ltd.
- 218 Saamya Biotech (India) Ltd.
- 219 Sajjala Bio Labs
- 220 Samsung Biologics Co. Ltd.
- 221 Saneca Pharmaceuticals a.s.
- 222 Sanofi S.A.
- 223 ScinoPharm Taiwan Ltd.
- 224 Seattle Genetics Inc.
- 225 Seqens Group
- 226 Serenity Pharmaceuticals Corp
- 227 Sermonix Pharmaceuticals
- 228 Shanghai Fosun Pharmaceutical(Group)Co., Ltd.
- 229 Shanghai Henlius Biotech, Inc.
- 230 Shenzhen Haorui Industrial Dev.
- 231 Shilpa Medicare Limited
- 232 Shiono Chemical Co., Ltd.
- 233 Shionogi & Co. Ltd.
- 234 Shreeji Pharma International
- 235 Sichuan Clover Biopharmaceuticals, Inc.
- 236 Siegfried Holdinngs AG
- 237 SM Biomed SDN. BHD
- 238 Smilax Laboratories Limited
- 239 SMS Pharmaceuticals Limited
- 240 Spark therapeutics
- 241 Srini Pharmaceuticals Ltd.
- 242 STADA Arzneimittel AG
- 243 Standard Chemical & Pharmaceutical Co.
- 244 Sterling Biotech Ltd.
- 245 Sumitomo Dainippon Pharma Co., Ltd.
- 246 Sun Pharmaceutical Industries Ltd.
- 247 Suven Life Science Ltd
- 248 Suzhou Ryway Biotech
- 249 Symbiotec Pharma lab Pvt., Ltd
- 250 Synergene Active Ingredients Pvt, Ltd.
- 251 Syn-tech chem. And Pharma.Co., Ltd.
- 252 Takeda Pharmaceutical Company Ltd.
- 253 Taro Pharmaceutical Industries Ltd.
- 254 TB Alliance
- 255 Temad Co.
- 256 Tetraphase Pharmaceutical Inc.
- 257 Teva Pharmaceutical Industries Ltd
- 258 TherapeuticMd Inc.
- 259 Theravance biopharma, Inc.
- 260 Thermo Fisher Scientific
- 261 TiGenix NV
- 262 Tonix Pharmaceuticals
- 263 Torrent Pharmaceuticals, Ltd.
- 264 trenzyme GmbH
- 265 Trimax Bio Sciences (P) Limited
- 266 Umicore N.V.
- 267 Unichem Laboratories Ltd.
- 268 Union Quimico Farmaceutica, S.A.
- 269 Unique Biotech Ltd.
- 270 USV Private Ltd.
- 271 Vaishali Pharma Ltd.
- 272 Vertex Pharmaceuticals
- 273 Viatris Inc. (Mylan N.V./Upjohn Pfizer Inc.)
- 274 Vir Biotechnology, Inc.
- 275 Viruj Pharmaceuticals Pvt, Ltd.
- 276 Vivimed labs Ltd.
- 277 Wanbury Ltd.
- 278 Wavelength Pharmaceuticals
- 279 Welt Care Lifesciences Pvt., Ltd.
- 280 Wockhardt
- 281 WuXi AppTec (STA Pharmaceutical Co., Ltd.)
- 282 WuXi Biologics
- 283 Xellia Pharmaceuticals
- 284 Xiamen Amoytop Biotech Co., Ltd.
- 285 Yabao Pharmaceutical Group Co., Ltd.
- 286 Yung Zip Chemical Industrial Co., Ltd.
- 287 Zambon group (Zach)
- 288 Zcl Chemicals Ltd.
- 289 Zhejiang Huahai Pharmaceutical Co., Ltd.
- 290 Zydus Cadila